Human alphaherpesvirus 3

Aug 26, 2019

NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND

Apr 16, 2019

NanoViricides Submits Pre-IND Briefing Documents to the US FDA

Mar 26, 2019

NanoViricides has Requested a Pre-IND Meeting with the US FDA

Feb 27, 2019

NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering

Feb 26, 2019

NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development

Feb 19, 2019

NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials

Feb 11, 2019

NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2:30pm

Feb 04, 2019

NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials